

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/>

Adverse events should also be reported to McNeil Products Limited on freephone 0808 238 9999.

Multi-Action ACTIFED Tablets (Triprolidine Hydrochloride, Pseudoephedrine Hydrochloride) Product Information:

Presentation:

Tablets containing triprolidine hydrochloride 2.5mg, pseudoephedrine hydrochloride 60mg.

Uses:

Symptomatic relief of upper respiratory tract disorders including allergic rhinitis, vasomotor rhinitis, the common cold, and influenza.

Dosage:

Adults and children over 12 years: one tablet every 4 to 6 hours (maximum of 4 times a day).

Contraindications:

This product should not be used in children under 12 years. This product is contraindicated in individuals with known hypersensitivity to pseudoephedrine, triprolidine, or to any of the product's excipients; cardiovascular disease including hypertension, diabetes mellitus, phaeochromocytoma, hyperthyroidism, closed angle glaucoma, severe acute or chronic kidney disease/renal failure. This product should not be used by individuals who are concomitantly taking beta blockers, or other sympathomimetic decongestants, and in individuals who are taking, or who have taken monoamine oxidase inhibitors (MAOIs) within the preceding 14 days. The concomitant use of MAOIs and pseudoephedrine-containing products may result in a rise in blood pressure and/or hypertensive crisis.

Precautions:

May cause drowsiness. This product should not be used to sedate a child. This product contains lactose monohydrate; patients with hereditary problems of galactose intolerance, total lactase deficiency, or glucose malabsorption should not take this medicine. Caution should be exercised in the presence of hepatic or moderate to severe renal impairment. Use with caution in occlusive vascular disease, acute or chronic asthma, chronic bronchitis, or emphysema. Patients with thyroid disease who are receiving thyroid hormones should not take Multi-Action Actifed Tablets, unless directed

by a physician. Patients with difficulty in urination, urinary retention, prostatic hyperplasia, or susceptibility to angle closure are advised to consult a physician before using this product. This product should be discontinued if hallucinations, restlessness, or sleep disturbances occur.

Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, sedatives, and tranquilisers. While taking Multi-Action ACTIFED Tablets, patients should be advised to avoid alcoholic beverages.

Severe skin reactions such as acute generalized exanthematous pustulosis (AGEP) may occur with pseudoephedrine containing products. If signs and symptoms such as pyrexia, erythema, or many small pustules are observed, administration of this medicine should be discontinued, and appropriate measures taken if needed.

Cases of ischaemic colitis have been reported with pseudoephedrine. This product should be discontinued, and medical advice sought if sudden abdominal pain, rectal bleeding, or other symptoms of ischaemic colitis develop.

Cases of ischaemic optic neuropathy have been reported with pseudoephedrine. This product should be discontinued if sudden loss of vision or decreased visual acuity such as scotoma occurs.

Cases of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) have been reported with the use of pseudoephedrine-containing products. The risk is increased in patients with severe or uncontrolled hypertension, or with severe acute or chronic kidney disease/renal failure. Pseudoephedrine should be discontinued, and immediate medical assistance sought if the following symptoms occur: sudden severe headache or thunderclap headache, nausea, vomiting, confusion, seizures and/or visual disturbances.

Please refer to Summary of Product Characteristics for detailed information.

Pregnancy and lactation:

This product should not be used during pregnancy or lactation unless the potential benefit of treatment to the mother outweighs the possible risks to the developing foetus or breastfeeding infant.

There are no adequate and well-controlled studies for pseudoephedrine or triprolidine, or for the combination of pseudoephedrine and triprolidine, in pregnant women.

Side effects:

Very Common: headache.

Common: insomnia, nervousness, dizziness, paradoxical stimulation, psychomotor impairment, somnolence, vision blurred, increased viscosity of bronchial secretion, dry mouth, gastrointestinal disorder, nausea, urinary retention (in men whom prostatic enlargement could have been an important predisposing factor).

Rare: blood disorder, hypersensitivity (cross-sensitivity with other sympathomimetics), confusional state, depression, sleep disorder, extrapyramidal disorder, seizure, tremor, palpitations, hypotension, liver disorder.

Not Known: anxiety, euphoric mood, excitability, hallucinations, irritability, paranoid delusions, restlessness, cerebrovascular accident, paraesthesia, posterior reversible encephalopathy syndrome (PRES)/reversible cerebral vasoconstriction syndrome (RCVS), psychomotor hyperactivity, ischaemic optic neuropathy, dysrhythmias, myocardial infarction/myocardial ischaemia, tachycardia, hypertension, dry throat, epistaxis, nasal dryness, abdominal discomfort, ischaemic colitis, vomiting, angioedema, pruritus, rash, severe skin reactions including acute generalised exanthematous pustulosis (AGEP), urticaria, dysuria, fatigue.

Please refer to Summary of Product Characteristics for detailed information.

RRP (ex-VAT): 12s: £5.11

Legal category: P

PL holder: McNeil Products Ltd, 50 – 100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK

PL number: 15513/0014.

Date of preparation: 17 May 2024